EyePoint reports expanded Phase 3 LUGANO trial results for DURAVYU
EyePoint expanded analysis of its LUGANO Phase 3 trial for DURAVYU in wet AMD, citing potential practice-changing data and renewed confidence just months before an anticipated FDA filing in 2027.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day